Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
Phase 2 Terminated
18 enrolled 14 charts
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
Phase 1 Terminated
203 enrolled 43 charts
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Phase 1 Terminated
17 enrolled
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
Phase 1 Terminated
62 enrolled
A Study Of The Selective PKC-β Inhibitor MS- 553
Phase 1/2 Terminated
60 enrolled 20 charts
UNITY-CLL
Phase 3 Terminated
603 enrolled 17 charts
GAUDEALIS
Phase 2 Terminated
5 enrolled 13 charts
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
Phase 2 Terminated
21 enrolled 17 charts
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Phase 1 Terminated
53 enrolled
A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
Phase 1 Terminated
47 enrolled
A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
Phase 1/2 Terminated
2 enrolled 7 charts
FT516 in Subjects With Advanced Hematologic Malignancies
Phase 1 Terminated
72 enrolled
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Phase 1 Terminated
98 enrolled
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
Phase 1/2 Terminated
55 enrolled 13 charts
OPERA-PLRG10
Phase 2 Terminated
1 enrolled
Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients
Phase 2 Terminated
3 enrolled 5 charts
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
Phase 1 Terminated
3 enrolled
Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Terminated
9 enrolled 9 charts
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
Phase 1 Terminated
1 enrolled 13 charts
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 1/2 Terminated
29 enrolled 18 charts
Phase 1b Safety and Efficacy Study of TRU-016
Phase 1 Terminated
87 enrolled
A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities
Phase 1 Terminated
38 enrolled
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
Phase 1 Terminated
26 enrolled 30 charts
A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Phase 1/2 Terminated
25 enrolled 21 charts
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Phase 3 Terminated
1,418 enrolled 20 charts
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Phase 3 Terminated
57 enrolled 12 charts
Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma
Phase 2 Terminated
2 enrolled 7 charts
FIL-GALILEO
Phase 2 Terminated
1 enrolled